Spinomix announced the appointments of Dr. Heiner Dreismanthen, PhD as the new Chairman of the Board of Directors. This announcement builds on the momentum initiated earlier this year when Spinomix closed of a Series A equity investment of $3 million (USD).
With more than 30 years of experience in the healthcare industry – including as former President and CEO of Roche Molecular Systems — Heiner is a well-recognized leader within the diagnostic community. A pioneer of the polymerase chain reaction (PCR), he also brings to Spinomix a history of successfully building robust portfolios and increasing revenue for the companies he has supported. His appointment brings the Board to six members.